AUS
NZ
UK
CA
USA
IND
Healt
Alcidion Group (ASX:ALC) Shares Rise Modestly in All Ordinaries Healthcare
January 15, 2026 07:48 PM AEDT| By SamAlcidion Group highlights descriptive revenue growth, sector-relative performance, and price-to-sales metrics within the All Ordinaries healthcare technology sector, reflecting market positioning trends.
Clinuvel Advances Pipeline as New Platform Gains Momentum
January 15, 2026 07:18 PM AEDT| By SamClinuvel Pharmaceuticals (ASX:CUV) continues to draw attention within the Australian healthcare space as it moves forward with a new controlled-release injectable platform, reinforcing its broader strategy within the ASX stock market ecosystem.
Neuren’s Daybue Momentum Draws Focus as Market Reassesses
January 15, 2026 06:45 PM AEDT| By SamNeuren Pharmaceuticals draws market attention as Daybue’s commercial progress and global expansion plans reshape expectations within the ASX biotech landscape.
Recce’s Synthetic Antibiotics Take Aim at Global Infections
January 15, 2026 05:40 PM AEDT| By SamAn in-depth look at Recce Pharmaceuticals’ synthetic anti-infective platform, global clinical progress, and relevance within the broader ASX stock market and healthcare innovation landscape.
New Board Direction Puts Mesoblast in Sharper Focus
January 15, 2026 04:50 PM AEDT| By SamMesoblast reshapes its board after a key regulatory milestone, signalling a transition from research focus toward commercial execution within the evolving Australian equity landscape.
Race Oncology update highlights healthcare activity across ASX 300 landscape
January 15, 2026 04:19 PM AEDT| By SamRace Oncology progresses a standard ordinary securities quotation application, reflecting healthcare sector activity and ongoing participation across key ASX indices.
Fresh ASX Move Puts Adheris Health Back in Market Focus
January 15, 2026 12:16 PM AEDT| By SamA routine ASX quotation update from a healthcare technology firm highlights how administrative steps support liquidity, transparency, and confidence across the Australian equity market.
DAYBUE Momentum Builds as Global Reach Expands
January 14, 2026 08:24 PM AEDT| By SamNeuren Pharmaceuticals strengthens its global footprint as DAYBUE expands through innovation, patient uptake, and international regulatory milestones, reinforcing long-term visibility in neurological care.
Imugene Advances Oncology Strategy Within ASX 300 Landscape
January 14, 2026 08:24 PM AEDT| By SamImugene confirmed a share quotation request following option conversions, reflecting standard capital structure updates within the Australian healthcare and biotechnology segment.
R&D Refund Strengthens Recce’s Innovation Momentum
January 14, 2026 05:02 PM AEDT| By SamRecce Pharmaceuticals receives a research tax incentive refund, strengthening funding for advanced anti-infective development and supporting continued progress across clinical and manufacturing initiatives.
DAYBUE Momentum Signals a New Growth Phase for Neuren
January 14, 2026 03:47 PM AEDT| By SamNeuren Pharmaceuticals advances its global presence as DAYBUE adoption grows, supported by innovation, patient access expansion, and international regulatory milestones shaping long-term healthcare relevance.
Insider Activity at Microba Life Sciences Draws Market Focus
January 14, 2026 03:19 PM AEDT| By SamAn in-depth look at insider ownership trends at Microba Life Sciences, examining governance signals, shareholder alignment, and broader implications within the Australian equity environment.
Why ASX 200 Healthcare Eyes Are Fixed on CSL’s Next Update
January 14, 2026 02:37 PM AEDT| By SamCSL remains a central figure in Australia’s healthcare narrative, with upcoming disclosures shaping sentiment across valuation, innovation, and long-term sector confidence.
Echo IQ Limited Advances Within Australia’s AI Diagnostics Sector
January 13, 2026 05:41 PM AEDT| By SamEcho IQ Limited (ASX:EIQ) focuses on AI diagnostics for structural heart disease, maintaining equity-funded operations and notable inclusion in the All Ordinaries.
Cochlear (ASX:COH) Expands US VA Access, ASX 50 Hearing Tech
January 13, 2026 05:35 PM AEDT| By SamAnalysis of Cochlear focusing on Nucleus Nexa system expansion, technology differentiation, and ASX 50 sector positioning, providing a factual view of operational and clinical developments.
Healthcare Technology Spotlight Builds Within All Ordinaries Index
January 13, 2026 04:42 PM AEDT| By SamFour D Medical remains part of Australia’s healthcare technology landscape, with index inclusion and sector activity highlighting its role within the ASX framework.
Healius (ASX:HLS) Shares Steady Within ASX 300 Healthcare Services
January 13, 2026 04:28 PM AEDT| By SamNeutral discussion of Healius Limited healthcare services model, operational scope, and industry context, outlining sector participation and ASX 300 classification without directional or promotional language.
Insider Ownership Signals Strength in Sigma Healthcare on asx 200
January 13, 2026 03:12 PM AEDT| By SamInsider alignment at Sigma Healthcare highlights governance strength, strategic consistency, and the importance of ownership structures when assessing healthcare companies in the Australian share market.
ASX 200 Spotlight: Why Ansell’s Latest Shift Has Markets Watching
January 13, 2026 02:55 PM AEDT| By SamAnsell’s leadership transition highlights how healthcare manufacturers navigate valuation scrutiny and market recalibration within Australia’s major equity benchmarks.
FDA clearance lifts cloud healthcare tech momentum on ASX
January 13, 2026 12:32 PM AEDT| By SamUS regulatory clearance strengthens Singular Health’s cloud imaging strategy, highlighting how Australian healthcare innovators are expanding globally through compliant, scalable digital solutions.
Advertise your brand on Kalkine Media